MedTrace Logo

Multiple Electrode Aggregometry & Clopidogrel Resistance

NCT01991093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2021-04-12

No results posted yet for this study

Summary

Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes. However, a significant number of patients experience recurrent events while on such therapy. The individual response to dual antiplatelet therapy is not uniform, and consistent findings across multiple investigations support the association between a lower degree of platelet inhibition, high on-treatment platelet reactivity, and the occurrence of atherothrombotic events \[1, 2\]. Particularly in diabetic patients, clopidogrel resistance is more prevalent compared with non-diabetics \[3,4\], which seems to contribute to the increased atherothrombotic risk in these patients compared with those without diabetes mellitus (DM) \[5\]. A number of platelet function instruments have now become available that are simple to use and can be utilized as point-of-care (POC) instruments in order to monitor antiplatelet therapy and potentially assess the risk of a recurrent event \[6\].

Conditions

  • Type 2 Diabetes Mellitus (T2DM)
  • Coronary Artery Disease (CAD)
  • Myocardial Infraction

Sponsors & Collaborators

  • Elpen Pharmaceutical Co. Inc.

    lead INDUSTRY

Principal Investigators

  • Argirios Tsantes, MD, Ass Professor · Head of Laboratory of Haematology & Blood Bank Unit, "Attiko" University General Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01991093 on ClinicalTrials.gov